GlassScriptPhysician profile
Gary Paul Korff
NPI 1063585495
$545.13
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $38.77 · 2021: $11.77.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $102.63 | 2019-2021 | |
| Pfizer INC. | $74.50 | 2019 | |
| Amgen INC. | $61.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $60.85 | 2019 | |
| Novo Nordisk INC | $37.65 | 2019 | |
| Mylan Specialty L.P. | $24.83 | 2019 | |
| Amarin Pharma, INC. | $23.26 | 2019 | |
| Neotract INC. | $22.71 | 2019 | |
| Abbott Laboratories | $20.83 | 2019 | |
| Lilly USA, LLC | $19.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.14 | 2019 | |
| Hologic Sales and Service, LLC | $16.85 | 2019 | |
| Boston Scientific Corporation | $14.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.75 | 2019 | |
| Sanofi Pasteur INC. | $12.01 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.86 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Korff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.